Considering that adiponectin has broad effects on metabolic tissues (e.g., skeletal muscle) and systemic insulin sensitivity, the extent to which the direct actions of adiponectin on the liver contribute to the anti-NAFLD effect of adiponectin remains to be determined. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.